Pinghan Huang

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

D. Gifford, Qiaobing Xu, Ying K. Tam, 2022, bioRxiv.

Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

Michael Z. Lin, C. Blish, A. Drelich, 2023, bioRxiv.

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

C. Blish, C. Tseng, S. Einav, 2024, Science Translational Medicine.